References
- Anderson JL, Adams CD, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148–304
- Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580–587
- Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75–83
- Aster RH, Curtis BR, Bougie DW, et al. Thromobocytopenia associated with the use of GPIIb/IIIa inhibitors: Position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost 2006; 4: 678–679
- Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIA. Blood 2002; 100: 2071–2076
- The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956–961
- Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with glycoprotein IIb/IIIa Receptor antagonists. Am J Cardiol 2006; 97: 426–429
- Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809–813
- Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985–992
- Package insert. ReoPro (abciximab). Eli Lilly, Indianapolis 2002
- The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443
- Nagge J, Jackevicius C, Dzavik V, et al. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003; 23: 374–379
- Onitilo AA. Delayed profound thrombocytopenia associated with eptifibatide. Am J Hematol 2006; 81: 984
- Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127(2 Suppl)53S–59S
- Karlheinz P, et al. Platelet activation as a potential mechanisim of GP IIb/IIa inhibitor—induced thrombocytopenia. Am J Cardiol 1999; 84: 519–524